Skip to content
Home » HPV vaccine reduces risk of vulvar and vaginal pre-cancers

HPV vaccine reduces risk of vulvar and vaginal pre-cancers


New research shows that the HPV vaccine reduces the risk of HPV-related vulvar and vaginal pre-cancers. Frequently, people focus on the HPV vaccine’s effectiveness in reducing the risk of cervical cancer, but the vaccine can reduce the risk of many HPV-related cancers.

I often read about the desire for a miracle cancer vaccine to be developed, yet we have one right now — the HPV vaccine.

This article will review this new study about how the HPV vaccine reduces the risk of vulvar and vaginal pre-cancerous lesions.

vulvar vaginal HPV vaccine

All about HPV and the HPV vaccine

I know I cut and paste this section into every article I write about HPV vaccines, but it’s the first step to HPV vaccine myth debunking. Some readers may be researching the vaccine for the first time, and they can find out how the HPV vaccine reduces cancer risks.

However, I try to update this section when necessary with new information about either the disease or the vaccine. If you’ve read this section 47 times, skip to the next section where I discuss the key points of this article.

Genital and oral human papillomavirus (HPV) infections are the most common sexually transmitted infections (STIs) in the USA.  HPV is generally transmitted from personal contact during vaginal, anal, or oral sex.

It is critical to note that there are more than 150 strains or subtypes of HPV that can infect humans; however, only 40 of these strains are linked to one or more different cancers. Moreover, of those 40 strains, most are fairly rare.

Although the early symptoms of HPV infections aren’t serious and many HPV infections resolve themselves without long-term harm, HPV infections are causally linked to many types of cancers in men and women. According to current medical research, here are some of the cancers that are linked to HPV:

In addition, there is some evidence that HPV infections are causally linked to skin and prostate cancers. The link to skin cancer is still preliminary, but there is much stronger evidence that HPV is linked to many prostate cancers.

HPV is believed to cause nearly 5% of all new cancers across the world, making it almost as dangerous as tobacco in that respect. According to published research, roughly 42 million persons in the USA are infected with disease-associated HPV, and 13 million persons acquire a new infection each year.

Each year in the United States, about 47,984 new cases of cancer are found in parts of the body where human papillomavirus (HPV) is often found — 26,280 among females, and 21,704 among males. 

Most individuals don’t even know they have the infection until the onset of cancer. The CDC states that over 37,800 HPV-related cancers are diagnosed in the USA every year. In 2022, there were approximately 1,505,394 HPV-related cancer cases and 755,303 deaths worldwide, with cervical cancer being the primary cause, accounting for 14.1 per 100,000 people.

There were two HPV vaccines on the world market before 2014. GSK, also known as GlaxoSmithKline, produced Cervarix, a bivalent vaccine that protects only against two HPV strains. Cervarix has been withdrawn from the US market (although available in many other markets) because of competition from the quadrivalent, which immunizes against four different HPV strains, and the 9-valent, which protects against nine HPV strains, Gardasil vaccines.

Merck manufactures Gardasil, probably the most popular HPV vaccine in the world. The first version of the vaccine, quadrivalent Gardasil, targets the two HPV genotypes known to cause about 70% of cervical cancer and two other HPV genotypes that cause genital warts. In Europe and other markets, Gardasil is known as Silgard.

The newer Gardasil 9, approved by the FDA in 2014, is a 9-valent vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It targets the four HPV strains found in the quadrivalent version, along with five additional ones that are linked to cervical and other HPV-related cancers. Both versions of Gardasil are prophylactic, meant to be given to females or males before they become exposed to possible HPV infection through intimate contact.

Gardasil is one of the easiest and best ways to prevent a few dangerous and, to abuse the definition slightly, common cancers that afflict men and women. Without a doubt, the HPV vaccine prevents cancer.

In the United States, the Advisory Committee on Immunization Practices (ACIP) currently recommends that preteen girls and boys aged 11 or 12 receive the HPV vaccine. The HPV vaccine is also recommended for teenage girls and young women up to the age of 26 who did not receive it when they were younger, and boys and young men up to the age of 21.

HPV is a sexually transmitted disease. HPV causes 37,800 cancers a year in the USA and over 1.5 million worldwide. The HPV vaccine prevents one from becoming infected by HPV, which means you are protected from these cancers.

three women smiling
Photo by Radomir Jordanovic on Pexels.com

HPV vaccine and vulvovaginal pre-cancers research

In a study published on 18 December 2025 in JAMA Oncology, Yunyang Deng, PhD, Karolinska Institute, Stockholm, and colleagues, analyzed medical records of 778,943 women, 32.9% of whom received at least one dose of the HPV vaccine. Median follow-up was 17 years for unvaccinated women, 12.2 years for those vaccinated between the ages of 10 and 16, and 10.8 years for those vaccinated at 17 years or older.

The researchers identified 98 cases of high-grade vulvovaginal (either vulvar or vaginal pre-cancers) lesions among vaccinated women and 547 cases in the unvaccinated group. The vaccinated cohort included women who received as few as one of the recommended three doses of the quadrivalent vaccine.

Here are the key results:

  • Women vaccinated against HPV had a 37% lower risk of developing high-grade vulvovaginal pre-cancerous lesions compared with unvaccinated women.
  • The risk reduction increased to 55% for those vaccinated between the ages of 10 and 16, emphasizing the benefits of early vaccination against HPV.

These results support other studies that show a lower risk of vulvovaginal pre-cancers and cancers among vaccinated women. A 2019 systematic review of phase 2 and 3 clinical studies showed a 71% reduction in the risk of vulvar and vaginal pre-cancers for women who received the HPV vaccine.

A 2021 observational study from Denmark showed a 52% reduction in the risk of high-grade vulvar pre-cancerous lesions, and a 70% reduction in the risk of high-grade vaginal lesions, in women who had received the HPV vaccine.

The authors wrote:

In this study, quadrivalent HPV vaccination was associated with reduced risk of high-grade vulvovaginal lesions, suggesting that expanding vaccination, especially at younger ages, could help prevent high-grade vulvovaginal lesions.

Summary

This new study adds to the body of evidence that the HPV vaccine not only prevents cervical cancers, but it also reduces the risk of high-grade vulvovaginal lesions, which can lead to vulvar and vaginal cancer.

As the initial cohort of men and women who received the HPV vaccine grows older, there will be more studies that will probably provide more evidence that the vaccine prevents other HPV-related cancers.

If you want to prevent cancer, the HPV vaccine is one of your best and safest methods to reduce your risk. Get the vaccine for yourself (if you are at the appropriate age) and your children (if they are of the appropriate age). It can save your lives.

Citations

Help the Skeptical Raptor keep writing about cancer-preventing vaccines

There are four ways you can help contribute to keeping this website running at full speed:

  1. GoFundMe.
  2. Subscribing via Patreon.
  3. Buying your favorite stuff on Amazon.
  4. Sharing this article on Social Media.

Don’t miss each new article!

We don’t spam! Read our privacy policy for more info.

Liked it? Take a second to support Michael Simpson on Patreon!
Become a patron at Patreon!


Discover more from Skeptical Raptor

Subscribe to get the latest posts sent to your email.

Discover more from Skeptical Raptor

Subscribe now to keep reading and get access to the full archive.

Continue reading